The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study
Open accessAbstract
Large numbers of hormone replacement therapies (HRTs) are available for the treatment of menopausal symptoms. It is still unclear whether some are more deleterious than others regarding breast cancer risk. The goal of this study was to assess and compare the association between different HRTs and breast cancer risk, using data from the French E3N cohort study. Invasive breast cancer cases were identified through biennial self-administered questionnaires completed from 1990 to 2002. During follow-up (mean duration 8.1 postmenopausal years), 2,354 cases of invasive breast cancer occurred among 80,377 postmenopausal women. Compared with HRT never-use, use of estrogen alone was associated with a significant 1.29-fold increased risk (95% confidence interval 1.02-1.65). The association of estrogen-progestagen combinations with breast cancer risk varied significantly according to the type of progestagen: the relative risk was 1.00 (0.83-1.22) for estrogen-progesterone, 1.16 (0.94-1.43) for estrogen-dydrogesterone, and 1.69 (1.50-1.91) for estrogen combined with other progestagens. This latter category involves progestins with different physiologic activities (androgenic, nonandrogenic, antiandrogenic), but their associations with breast cancer risk did not differ significantly from one another. This study found no evidence of an association with risk according to the route of estrogen administration (oral or transdermal/percutaneous). These findings suggest that the choice of the progestagen component in combined HRT is of importance regarding breast cancer risk; it could be preferable to use progesterone or dydrogesterone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As mentioned above, although long-term use of progestins is associated with a small increase in the risk of breast cancer, the use of progesterone seems to be free of that risk [16,17].”
From HRT in Women Undergoing Pelvic Clearance for Endometriosis—A Case Report and a National Survey (2023) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, current evidence suggests that the use of progesterone with oestrogen is not associated with any long-term increase in breast cancer risk, while the use of progestins carries 16–69% increased risk (depending on the type of progestin) compared with HRT never-use [16,17].”
From HRT in Women Undergoing Pelvic Clearance for Endometriosis—A Case Report and a National Survey (2023) · cites this paper as [16]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Breast cancer and hormone-replacement therapy in the Million Women Study
(2003) · The Lancet · doi:10.1016/s0140-6736(03)14065-2 · Cited by 2,993
(1997) · The Lancet · doi:10.1016/s0140-6736(97)08233-0 · Cited by 2,458
Self-citationRiboli, E., Hunt, K., Slimani, N., Ferrari, P., Norat, T., Fahey, M., Charrondière, U., Hémon, B., Casagrande, C., Vignat, J., et al. (2002) · Public Health Nutrition · doi:10.1079/phn2002394 · Cited by 1,866
Self-citationEvaluating medication effects outside of clinical trials: new-user designs
Ray, W. A. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg231 · Cited by 1,646
Breast cancer and hormone-replacement therapy: the Million Women Study
Beral, V., Banks, E., Reeves, G., & Bull, D. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14596-5 · Cited by 1,273
Physiological Action of Progesterone in Target Tissues*
Graham, J. D., & Clarke, C. L. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.4.0308 · Cited by 1,008
Stefanick, M. L., Anderson, G. L., Margolis, K. L., Hendrix, S. L., Rodabough, R. J., Paskett, E. D., Lane, D. S., Hubbell, F. A., Assaf, A. R., Sarto, G. E., et al. (2006) · JAMA · doi:10.1001/jama.295.14.1647 · Cited by 571
Postmenopausal Hormone Therapy and Change in Mammographic Density
Greendale, G. A., Reboussin, B. A., Slone, S., Wasilauskas, C., Pike, M. C., & Ursin, G. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.1.30 · Cited by 419
Fournier, A., Berrino, F., Riboli, E., Avenel, V., & Clavel‐Chapelon, F. (2005) · International Journal of Cancer · doi:10.1002/ijc.20710 · Cited by 403
Self-citation
Cited by
Epidemiological characteristics of and risk factors for breast cancer in the world
Momenimovahed, Z., & Salehiniya, H. (2019) · Breast Cancer: Targets and Therapy · doi:10.2147/bctt.s176070 · Cited by 1,050
2016 IMS Recommendations on women’s midlife health and menopause hormone therapy
Baber, R. J., Panay, N., & Fenton, A. (2016) · Climacteric · doi:10.3109/13697137.2015.1129166 · Cited by 964
The 2022 hormone therapy position statement of The North American Menopause Society
(2022) · Menopause · doi:10.1097/gme.0000000000002028 · Cited by 977
Treatment of symptoms of the menopause: an Endocrine Society Clinical Practice Guideline
Stuenkel, C. A., Davis, S. R., Gompel, A., Lumsden, M. A., Murad, M. H., Pinkerton, J. V., & Santen, R. J. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2236 · Cited by 884
Metadata
- Authors
- Fournier, A., Berrino, F., & Clavel-Chapelon, F.
- Affiliations
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- ORCID
- Berrino, Franco
- Venue
- Breast Cancer Research and Treatment
- Published
- 2007-02-27
- Volume
- 107
- Issue
- 1
- Pages
- 103-111
- ISSN
- 0167-6806 (ISSN-L)
- 1573-7217
- PMC
- PMC2211383
- OpenAlex
- W2051559140
- Cited by
- 693
- References
- 28
- Citations by year
- 2026: 32 · 2025: 33 · 2024: 27 · 2023: 30 · 2022: 37 · 2021: 41 · 2020: 91 · 2019: 43 · 2018: 32 · 2017: 22 · 2016: 24 · 2015: 26 · 2014: 28 · 2013: 41 · 2012: 34
- FWCI
- 30.07
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Breast Cancer Research and Treatment (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Health Sciences › Medicine › Oncology › Cancer Risks and Factors
- Keywords
- hormone replacement therapy, breast cancer risk, estrogen alone, progestogens, dydrogesterone, progesterone, postmenopausal women, E3N cohort
- MeSH terms
- Adult, Aged, Breast Neoplasms, Dydrogesterone, Estrogens, Female, Humans, Middle Aged, Neoplasm Invasiveness, Progestins, Progesterone, Risk, Cohort Studies, Postmenopause, Hormone Replacement Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. https://app.cochat.ai/papers/10.1007/s10549-007-9523-x
- The paper
- Fournier, A., Berrino, F., & Clavel-Chapelon, F. (2007). Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-007-9523-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.